Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock
MPM BioVentures 2018, a 10% shareholder and director of Entrada Therapeutics, sold 62,714 shares of the company's common stock totaling $461,545. The transactions took place over three days in August 2026, with prices fluctuating between $7.06 and $7.54 per share. The stock experienced a decline of about 8% over the week, trading at $7 against a market capitalization of $252 million.
InvestingPro analysis suggests the stock is undervalued, with a Fair Value of $7.95. The fund disposed of 21,623 shares on August 24 at an average price of $7.34, 26,522 shares on August 25 at $7.54, and 14,569 shares on August 26 at $7.06. After these sales, MPM BioVentures 2018, L.P. and its affiliated entities now own 4,318,348 shares of Entrada Therapeutics.
The company's management is facing financial challenges, with analysts maintaining price targets between $11 and $25 per share. Despite this, the investment fund continues to hold a significant stake in the company.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
